Literature DB >> 27249209

Therapeutic options for cutaneous lupus erythematosus: recent advances and future prospects.

Joshua Chang1,2, Victoria P Werth1,2.   

Abstract

INTRODUCTION: Treatment and prevention are of critical importance in patients with cutaneous lupus erythematosus (CLE), as the disease can have a devastating effect on patient well-being and quality of life. AREAS COVERED: We conducted a selective search of the PubMed database for articles published between December 2010 and November 2015. This review encompasses both non-pharmaceutical (photoprotection, smoking cessation, drug withdrawal, and vitamin D replacement) and pharmaceutical (topicals, antimalarials, immunosuppressives, biologics, etc.) interventions used in the treatment of CLE. Expert Commentary: Recent work has expanded our understanding of established therapies as well as introduced new treatments for consideration, though existing medications still prove inadequate for a subset of patients. Changes in trial design may help to alleviate this issue.

Entities:  

Keywords:  Cutaneous Lupus Erythematosus Disease Area and Severity IndexTM (CLASITM); Cutaneous lupus erythematosus; antimalarials; biologics; immunomodulators; immunosuppressives; topical calcineurin inhibitors

Mesh：

Substances：

Year:  2016        PMID： 27249209      PMCID： PMC5843480          DOI： 10.1080/1744666X.2016.1188006

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN： 1744-666X            Impact factor:   4.473


  125 in total

1.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

2.  Treatment of Scarring Alopecia in Discoid Variant of Chronic Cutaneous Lupus Erythematosus With Tacrolimus Lotion, 0.3.

Authors:  Emily C Milam; Sarika Ramachandran; Andrew G Franks
Journal:  JAMA Dermatol       Date:  2015-10       Impact factor: 10.282

Review 3.  Adherence to treatment in systemic lupus erythematosus patients.

Authors:  Nathalie Costedoat-Chalumeau; Jacques Pouchot; Gaëlle Guettrot-Imbert; Véronique Le Guern; Gaëlle Leroux; Donata Marra; Nathalie Morel; Jean-Charles Piette
Journal:  Best Pract Res Clin Rheumatol       Date:  2013-06       Impact factor: 4.098

Review 4.  Efficacy and safety of biologic therapies for systemic lupus erythematosus treatment: systematic review and meta-analysis.

Authors:  Helena Hiemisch Lobo Borba; Astrid Wiens; Thais Teles de Souza; Cassyano Januário Correr; Roberto Pontarolo
Journal:  BioDrugs       Date:  2014-04       Impact factor: 5.807

Review 5.  Epigenetics in the treatment of systemic lupus erythematosus: potential clinical application.

Authors:  Yu Guo; Amr H Sawalha; Qianjin Lu
Journal:  Clin Immunol       Date:  2014-09-16       Impact factor: 3.969

6.  Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.

Authors:  Ellen M Ginzler; Daniel J Wallace; Joan T Merrill; Richard A Furie; William Stohl; W Winn Chatham; Arthur Weinstein; James D McKay; W Joseph McCune; Z John Zhong; William W Freimuth; Michelle A Petri
Journal:  J Rheumatol       Date:  2013-11-01       Impact factor: 4.666

7.  Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials.

Authors:  Susan Manzi; Jorge Sánchez-Guerrero; Joan T Merrill; Richard Furie; Dafna Gladman; Sandra V Navarra; Ellen M Ginzler; David P D'Cruz; Andrea Doria; Simon Cooper; Z John Zhong; Douglas Hough; William Freimuth; Michelle A Petri
Journal:  Ann Rheum Dis       Date:  2012-05-01       Impact factor: 19.103

8.  Adherence to Oral and Topical Medications in Cutaneous Lupus Erythematosus is not Well Characterized.

Authors:  Michael E Farhangian; William W Huang; Steven R Feldman
Journal:  Dermatol Ther (Heidelb)       Date:  2015-04-22

9.  Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials.

Authors:  William Stohl; Joan T Merrill; R John Looney; Jill Buyon; Daniel J Wallace; Michael H Weisman; Ellen M Ginzler; Blaire Cooke; Donna Holloway; Arunan Kaliyaperumal; Kameswara Rao Kuchimanchi; Tsui Chern Cheah; Erik Rasmussen; John Ferbas; Shelley S Belouski; Wayne Tsuji; Debra J Zack
Journal:  Arthritis Res Ther       Date:  2015-08-20       Impact factor: 5.156

10.  Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study.

Authors:  Michelle Petri; Daniel J Wallace; Alberto Spindler; Vishala Chindalore; Kenneth Kalunian; Eduardo Mysler; C Michael Neuwelt; Gabriel Robbie; Wendy I White; Brandon W Higgs; Yihong Yao; Liangwei Wang; Dominique Ethgen; Warren Greth
Journal:  Arthritis Rheum       Date:  2013-04
View more
  3 in total

Review 1.  Advancing understanding, diagnosis, and therapies for cutaneous lupus erythematosus within the broader context of systemic lupus erythematosus.

Authors:  Kristen L Chen; Rebecca L Krain; Victoria P Werth
Journal:  F1000Res       Date:  2019-03-25

2.  Interventions for cutaneous disease in systemic lupus erythematosus.

Authors:  Cora W Hannon; Collette McCourt; Hermenio C Lima; Suephy Chen; Cathy Bennett
Journal:  Cochrane Database Syst Rev       Date:  2021-03-09

Review 3.  Cutaneous lupus erythematosus: A review of the literature.

Authors:  Stephanie Clare Blake; Benjamin Silas Daniel
Journal:  Int J Womens Dermatol       Date:  2019-07-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.